Biopharma deal value surged in the first five months of 2026, reaching $135.36 billion—above every prior year through the same window—and May delivered the year’s biggest month at $41.78 billion. The report attributes the momentum largely to China-linked partnerships, citing major U.S.-China transactions including Bristol Myers Squibb’s $15.2 billion collaboration with Jiangsu Hengrui and Pfizer’s $10.5 billion deal with Innovent Biologics. The scale of deals suggests renewed confidence in cross-border development strategies and accelerated partnering timelines. For biotech leaders, it also affects competitive positioning for pipeline licensing, co-development, and regional commercialization plans.